Durable clinical responses using PD-1/L1-based therapy have been associated with a T cell-inflamed tumor microenvironment (TME) favoring the infiltration of functional cytotoxic T lymphocytes (CTLs) (7). Here, PDCD1 is linked to neoplasm.